E
Ernexa Therapeutics Inc. ERNA
$1.49 $0.0573.98% NASDAQ
Recommendation
Prev Close
$1.43
Volume
13,085
Avg Vol (90D)
61,964
Market Cap
$10.99M
Dividend & Yield
--
52-Week Range
$1.43 - $28.65
P/E (TTM)
--
EPS (TTM)
-$78.93
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements
7/9/2025 - Globe Newswire
Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development
6/25/2025 - Globe Newswire
Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement
6/24/2025 - Globe Newswire
Eterna Therapeutics Implements 1-for-15 Reverse Stock Split
6/12/2025 - TipRanks Financial Blog
Eterna Therapeutics (ERNA) Trading Halted Pending News Announcement ERNA Stock News
6/12/2025 - GuruFocus
Eterna Therapeutics trading halted, news pending
6/11/2025 - The Fly
Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split
6/10/2025 - Globe Newswire
Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025
5/28/2025 - Globe Newswire
Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations
5/14/2025 - Globe Newswire
Ernexa Therapeutics Announces Participation in the D. Boral Capital Inaugural Global Conference
5/8/2025 - Newsfile Corp. - News Releases
Ernexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025
4/29/2025 - Globe Newswire
Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025
4/22/2025 - Globe Newswire
Eterna Therapeutics Inc. (NASDAQ:ERNA) Short Interest Down 42.8% in March
4/18/2025 - Ticker Report
Ernexa Therapeutics Closes New Funding Round
4/3/2025 - Globe Newswire
Eterna Therapeutics Changes Name to Ernexa Therapeutics to Reflect New Strategic Focus on ...
3/25/2025 - GuruFocus
Eterna Therapeutics Changes Name to Ernexa Therapeutics to Reflect New Strategic Focus on Ovarian Cancer and Autoimmune Disease
3/25/2025 - Globe Newswire
Eterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory ...
2/26/2025 - GuruFocus
Eterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory Board to Advance Cell Therapy Pipeline
2/26/2025 - Globe Newswire
Eterna Therapeutics Announces Expansion of Scientific Advisory Board
1/28/2025 - GuruFocus
Eterna Therapeutics Announces Expansion of Scientific Advisory Board
1/28/2025 - Globe Newswire
Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in ...
1/14/2025 - GuruFocus
Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer
1/14/2025 - Globe Newswire
Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors
1/9/2025 - GuruFocus
Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors
1/9/2025 - Globe Newswire
Eterna Therapeutics Launches Research to Evaluate its Lead Induced Mesenchymal Stem Cell Therapy Candidate's (ERNA-101) Ability to Induce and Modulate Antitumor Immunity in Ovarian Cancer and Breast Cancer Models
12/3/2024 - Globe Newswire
Income Statement
Total Revenue (TTM)
$488.00K
EBITDA (TTM)
-$11.67M
EBIT (TTM)
-$11.76M
Net Income (TTM)
-$43.70M
Balance Sheet
Total Assets (Q)
$7.58M
Total Debt (Q)
$593.00K
Total Liabilities (Q)
$3.14M
Book Value Per Share (Q)
$0.5937
Cash Flow
Cash from Operations (TTM)
-$14.43M
Cash from Investing (TTM)
-$19.00K
Cash from Financing (TTM)
$12.08M
Net Change in Cash (TTM)
-$2.37M
Filings
Filing Date
Wednesday, August 13, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Nov 10 and 14 (est)
Price History
Loading...
Beta
1.40
7-Day Total Return
-5.99%
30-Day Total Return
-22.40%
60-Day Total Return
-54.43%
90-Day Total Return
-45.96%
Year to Date Total Return
-73.08%
1-Year Total Return
-94.48%
2-Year Total Return
-96.10%
3-Year Total Return
-98.76%
5-Year Total Return
--
52-week Low
Aug 25, 2025 - $1.43
52-week High
Aug 30, 2024 - $28.65
Valuation
Market Cap
$10.99M - Nano Cap
Enterprise Value
$7.27M
Price/Sales (TTM)
15.21
Price/Book (Q)
2.41
Dividends and Shares
Shares Outstanding
5.18
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.ernexatx.com
Phone Number
212 582 1199
Address
1035 Cambridge Street
Cambridge, MA 02141
Country
United States
Year Founded
2018
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company’s... more
NASDAQ 08/26/2025 3:59PM Eastern Quotes delayed